Isarna Therapeutics' Series B Round

Isarna Therapeutics raised a round of funding on November 30, 2005. Investors include MIG Fonds.

Isarna Therapeutics has a commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. The company is advancing a unique pipeline of novel oligonucleo…

Articles about Isarna Therapeutics' Series B Round: